Conference Presentation

 

Injection Drug Use and Hepatitis C

Brian R. Edlin, M.D.

NIH Consensus Development Conference on
Management of Hepatitis C: 2002 

Bethesda, Maryland

June 10-12, 2002


Main New and Noteworthy                    Conference Index               Home

Injection drug users (IDUs) constitute the largest group of persons infected with the hepatitis C virus (HCV) in the United States, and most new infections occur in IDUs. Controlling the HCV epidemic, therefore, will require developing, testing, and implementing prevention and treatment strategies that will be effective in persons who inject drugs. Preventing morbidity and mortality from HCV will require reducing exposure to HCV, reducing infection among those exposed, and reducing disease among those infected. Injection drug use could be greatly reduced if all those who needed substance abuse treatment could get it (prevention of exposure). HCV spread among drug users can be prevented if drug users have access to sterile syringes, HCV counseling and testing, and outreach programs that teach them how they can avoid acquiring and transmitting the virus (prevention of infection). Finally, barriers to medical treatment must be overcome so that drug users can benefit from advances in HCV treatment (prevention of disease). (1) HCV treatment may also reduce transmission (prevention of infection), because HCV-infected IDUs are the source for most HCV transmission in the United States. Efforts are particularly important to identify persons with new HCV infections, in whom treatment may be more effective during the acute phase than later, and those with advanced hepatic fibrosis, in whom treatment may improve survival.

Caring for drug users presents special challenges to the health care team that require patience, experience, and tolerance. Fortunately, substantial research and clinical experience in the prevention and management of chronic viral infections among IDUs, especially HIV infection, has led to the development of effective principles for engaging drug users in health care relationships (Table). (2–5) Learning from this experience will be critical for efforts to control HCV. Successful programs invariably adopt a respectful approach to substance users, understand the medical and behavioral sequelae of addiction, and refrain from moralistic judgments. These strategies reflect a harm reduction approach. (6,7) Harm reduction strategies help patients reduce high-risk behaviors without imposing unrealistic demands for global change. When ceasing all drug use is not likely in the immediate future, other measures must be taken to help patients reduce the harmful consequences of injection drug use. (8,9) Decisions about the treatment of HCV infection in patients who use illicit drugs, as in other patients, should be made by the patients together with their physicians based on individualized risk-benefit assessments. (1) Adherence, psychological side effects, and the possibility of reinfection present challenges to effective treatment for some drug users.

Fortunately, an array of effective strategies exists to overcome each of these challenges. Attention to ensuring optimal adherence is important for all patients, not just those who use drugs. (10) This is so because although certain risk factors for noncompliance have been identified, including depression, psychological stress, homelessness, lack of social support, and drug use, physicians are not able to predict accurately which patients will adhere to a treatment regimen. (11) Effective strategies for improving adherence range from basic clinical practices—such as establishing a consistent, trusting physician-patient relationship, providing clear information

 

Table. Principles for managing health care relationships with substance-using patients.

1. Establish a climate of mutual respect.

2. Maintain a professional approach that reflects the aim of enhancing patients’ well-
    being; avoid creating an atmosphere of blame or judgment.

3. Educate patients about their medical status, proposed treatments, and their side effects.

4. Include patients in decision-making.

5. If possible, establish a multidisciplinary team consisting of primary care physicians, HIV
    specialists, psychiatrists, social workers, and nurses.

6. Have a single primary care provider coordinate the care delivered by such a team to
    maximize consistency and continuity.

7. Define and agree on the roles and responsibilities of both the health care team and the
    patient.

8. Set appropriate limits and respond consistently to behavior that violates those limits. 9.
    Minimize barriers to participation (penalties for missed visits, etc.).

10.Recognizing that patients must set their own goals for behavior change, work with
     patients to achieve commitment to realistic goals for healthier behaviors.

11. Acknowledge that abstinence is not always a realistic goal; emphasize risk reduction
     measures for patients who continue to use drugs.

12. Acknowledge that sustaining abstinence is difficult and that success may require
     several attempts. 

13. Be familiar with local resources for the treatment of drug users.
 


about intended effects and side effects of medication, and paying careful attention to perceived side effects—to specialized tools such as electronic reminder systems, directly observed therapy ,
and cash incentives. (12–17) Simplifying complex treatment regimens, treating depression, or helping a homeless patient find housing can help improve adherence. Patients may also benefit from counseling addressing individual barriers to and facilitators of adherence in the patient’s life. 

The psychological side effects of interferon-based regimens for the treatment of HCV infection are of concern in all patients. Interferon may have severe psychological side effects in patients with or without pre-existing psychiatric disorders. (18,19) To minimize psychological toxicity, all patients should be screened for depression and other mental health conditions before undergoing HCV treatment, treated for these conditions if necessary, and monitored for them during HCV treatment.

Because those successfully completing HCV therapy may be at risk for reinfection, drug users need detailed counseling and support to avoid risky injection practices in case they continue or return to injecting drugs. Those who inject drugs after receiving effective treatment for HCV infection can avoid reinfection by using a new sterile syringe for each injection and by not sharing their injection equipment with other users. (20,21) There are 174 syringe exchange programs in 120 cities in 34 states in the United States, and the number is increasing yearly. For drug users without access to such programs, physicians in at least 46 states are allowed by law to prescribe syringes so that their patients can avoid acquiring and transmitting bloodborne infections. (22–24) IDUs can master safe injection practices, and many do inject safely. When given access to sterile syringes, IDUs readily make use of them, reducing their high-risk behavior (25–27) and rates of disease transmission. (28,29) Physicians should refer patients who inject drugs to syringe exchange programs or, if necessary, prescribe syringes for them. HCV may be more readily transmitted than the human immunodeficiency virus (HIV) through the sharing of injection equipment other than syringes, such as “cookers” (bottle caps, spoons, and other containers used to dissolve drugs) and “cottons” (filters used to draw up the drug solution into a syringe). (30) Thus, it is particularly important for physicians to instruct their patients not to share these items. (20,21)

All injection drug users should be offered treatment for substance abuse and such treatment should be provided to those wishing it. Medical services should be integrated with substance abuse treatment. (3) Alcohol treatment is particularly important because of the strong effect of heavy alcohol intake on the progression of hepatitis C. Finally, all patients with HCV infection should be instructed in how to avoid transmitting the infection to others. Patients should be warned that their blood may be infectious even in minute quantities. Those who inject drugs should be instructed not to share syringes or any other injection equipment with other persons and to avoid blood contact with others. They should be given biohazard sharps containers or instructed to safely dispose of injection equipment in puncture-resistant containers. (31)

Clinical Data

There is abundant evidence that when treatment strategies for drug users take into account the circumstances of their lives, very high rates of adherence can be achieved. (11,15–17,32–38) Several recent studies have demonstrated the safety and effectiveness of hepatitis C treatment in drug users, even when they are not completely abstinent from drug use. (39–41) Backmund et al. reported a 36 percent sustained virologic response rate in 50 injection drug users who were treated simultaneously for HCV infection and substance abuse, even though 80 percent of the patients  relapsed to drug use. (39) Sustained response rates were not significantly different for patients who relapsed and those who did not. All patients were treated and supervised by physicians who specialized in both hepatology and addiction medicine. Patients who relapsed to drug use were offered opiate replacement therapy and were allowed to continue their HCV treatment even if they injected heroin again. The strongest predictor of virologic response was whether patients continued to keep their appointments; 45 percent of those who kept > 67 percent of their appointments but only 6 percent of those who did not had sustained virologic responses. This study demonstrates the importance of combining expertise in both hepatology and substance abuse and maintaining strong relationships with patients that can be sustained even through relapse to drug use.

Because those successfully completing HCV therapy may be at risk for reinfection, drug users need detailed counseling and support to avoid risky injection practices in case they continue or return to injecting drugs. Those who inject drugs after receiving effective treatment for HCV infection can avoid reinfection by using a new sterile syringe for each injection and by \\\not sharing their injection equipment with other users. (20,21) There are 174 syringe exchange programs in 120 cities in 34 states in the United States, and the number is increasing yearly. For drug users without access to such programs, physicians in at least 46 states are allowed by law to prescribe syringes so that their patients can avoid acquiring and transmitting bloodborne infections. (22–24) IDUs can master safe injection practices, and many do inject safely. When given access to sterile syringes, IDUs readily make use of them, reducing their high-risk behavior (25–27) and rates of disease transmission. (28,29) Physicians should refer patients who inject drugs to syringe exchange programs or, if necessary, prescribe syringes for them. HCV may be more readily transmitted than the human immunodeficiency virus (HIV) through the sharing of injection equipment other than syringes, such as “cookers” (bottle caps, spoons, and other containers used to dissolve drugs) and “cottons” (filters used to draw up the drug solution into a syringe). (30) Thus, it is particularly important for physicians to instruct their patients not to share these items. (20,21)

All injection drug users should be offered treatment for substance abuse and such treatment should be provided to those wishing it. Medical services should be integrated with substance abuse treatment. (3) Alcohol treatment is particularly import ant because of the strong effect of heavy alcohol intake on the progression of hepatitis C. Finally, all patients with HCV infection should be instructed in how to avoid transmitting the infection to others. Patients should be warned that their blood may be infectious even in minute quantities. Those who inject drugs should be instructed not to share syringes or any other injection equipment with otherpersons and to avoid blood contact with others. They should be given biohazard sharps containers or instructed to safely dispose of injection equipment in puncture-resistant containers. (31)

Clinical Data

There is abundant evidence that when treatment strategies for drug users take into account the circumstances of their lives, very high rates of adherence can be achieved. (11,15–17,32–38) Several recent studies have demonstrated the safety and effectiveness of hepatitis C treatment in drug users, even when they are not completely abstinent from drug use. (39–41) Backmund et al. reported a 36 percent sustained virologic response rate in 50 injection drug users who were treated simultaneously for HCV infection and substance abuse, even though 80 percent of the patients relapsed to drug use. (39) Sustained response rates were not significantly different for patients who relapsed and those who did not. All patients were treated and supervised by physicians who specialized in both hepatology and addiction medicine. Patients who relapsed to drug use were offered opiate replacement therapy and were allowed to continue their HCV treatment even if they injected heroin again. The strongest predictor of virologic response was whether patients continued to keep their appointments; 45 percent of those who kept > 67 percent of their appointments but only 6 percent of those who did not had sustained virologic responses. This study demonstrates the importance of combining expertise in both hepatology and substance abuse and maintaining strong relationships with patients that can be sustained even through relapse to drug use.

Sylvestre et al. have treated 67 methadone maintenance patients with combination interferon/ribavirin, with an interim sustained virologic response rate in the first 59 patients of 29 percent, a rate identical to that in a comparison group of nonopioid-dependent patients. (40) No serious side effects occurred, although 61 percent of the patients had a prior psychiatric diagnosis. Response rates were not significantly different in patients who did or did not have 6 months of sobriety, nor in patients who did or did not consume alcohol. They were not significantly worse in patients who continued using drugs unless they used every day. This study demonstrates that HCV can be effectively treated in patients receiving maintenance opiate replacement therapy despite substantial pre-existing psychiatric disease and despite ongoing, intermittent drug use.

Finally, Backmund et al. reported no reinfection during 24 weeks in 10 patients who continued to inject heroin. (39) They carefully instructed their patients how to avoid acquiring HCV when injecting drugs. Dalgard et al. reported one reinfection during 5 years in 9 patients who relapsed to injection drug use after sustained virologic responses to HCV treatment. (41)

Success in treating HCV infection in IDUs will require collaboration between experts in hepatitis and substance use to create programs specifically designed for drug users. Efforts to control HCV, including both prevention and treatment, can benefit from the expertise of those with experience working with drug users. Substance abuse treatment professionals have expertise working with drug users in treatment. Harm reduction workers and many substance abuse researchers have expertise working with out-of-treatment drug users. And many AIDS medical providers have expertise providing medical care to drug users both in and out of substance abuse treatment. Involvement of these professionals in HCV prevention and treatment efforts will greatly improve their effectiveness. A sound policy for the control of the hepatitis C epidemic will require implementing prevention and treatment programs designed for IDUs, the group most severely affected by the epidemic. (42) Controlling the HCV epidemic, therefore, will require further research to develop and test prevention and treatment strategies that will be effective in persons who inject drugs. In the meantime, however, substantial progress can be made to control hepatitis C if existing knowledge and resources are brought to bear.

References

1. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001;345:211–4.

2. O’Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection-drug users with human immunodeficiency virus infection. New Engl J Med 1994;331:450–9.

3. Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y. Integrating primary medical care with addiction treatment: a randomized controlled trial. JAMA 2001;286(14):1715–23. 81

4. Batki SL, Sorensen JL. Care of injection drug users with HIV. In: Cohen PT, Sande MS, Volberding PA, eds. The AIDS knowledge base: a textbook on HIV disease from the University of California, San Francisco and San Francisco General Hospital. 3rd ed .Philadelphia, PA: Lippincott, Williams and Wilkins, 1999. Available at URL: http://hivinsite.ucsf.edu/InSite.jsp?page=kb-03&doc=kb-03-03-06.

5. Wartenberg AA. HIV disease in the intravenous drug user: role of the primary care physician. J Gen Intern Med 1991;6(1 suppl):S35–40.

6. Des Jarlais DC, Friedman SR, Ward TP. Harm reduction: a public health response to the AIDS epidemic among injecting drug users. Annual Review of Public Health 1993;14:413–50.

7. Marlatt GA, ed. Harm reduction: Pragmatic strategies for managing high risk behaviors. New York: Guilford Press, 1998.

8. Robertson R, ed. Management of drug users in the community: a practical handbook. London: Arnold, 1998.

9. Gostin L. Waging a war on drug users: an alternative public health vision. Law Med Health Care 1990;18(4):385–94.

10. Sackett DL, Snow JC. The magnitude of compliance and noncompliance. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in health care. Baltimore: Johns Hopkins University Press, 1979, p. 11–22.

11. Bangsberg DR, Moss A. When should we delay highly active antiretroviral therapy? J Gen Intern Med 1999;14:446–8.

12. Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999;13(Suppl 1):S61–72.

13. Panel on Clinical Practices for Treatment of HIV Infection. Adherence to potent antiretroviral therapy. In: Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Rockville, MD: U.S. Department of Health and Human Services, 2001. Available from URL: http://www.hivatis.org/guidelines/adult/text/adherence.html.

14. Reiter GS, Stewart KE, Wojtusik L, et al. Elements of success in HIV clinical care: multiple interventions that promote adherence. Topics in HIV Medicine 2000;8:21–30.

15. Bamberger J, Unick J, Klein P, Fraser M, Chesney M, Katz MH. Helping the urban poor stay with antiretroviral therapy. Am J Public Health 2000;90:699–701.

16. Lorvick J, Thompson S, Edlin BR, Kral AH, Lifson AR, Watters JK. Incentives and accessibility: a pilot study to promote adherence to TB prophylaxis in a high-risk community. Journal of Urban Health 1999;76:461–7.

17. Chaisson RE, Barnes GL, Hackman J, Watkinson L, Kimbrough L, Metha S, Cavalcante S, Moore RD. A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. Am J Med. 2001;110(8):610–5.

18. Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987;147:1577–80.

19. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241–3.

20. U.S. Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Rockville, MD: Agency for Healthcare Research and Quality, 1996:591. Available at URL: http://www.ahcpr.gov/clinic/2ndcps/drugab.pdf.

21. HIV prevention bulletin: medical advice for persons who inject illicit drugs. Rockville, MD: Public Health Service, May 9, 1997. Available at URL: http://www.cdc.gov/hiv/pubs/hiv_prev.pdf.

22. Burris S, Lurie P, Abrahamson D, Rich JD. Physician prescribing of sterile injection equipment to prevent HIV infection: time for action. Ann Intern Med 2000;133:218–26.

23. Rich JD, Macalino GE, McKenzie M, Taylor LE, Burris S. Syringe prescription to prevent HIV infection in Rhode Island: a case study. Am J Public Health 2001;91(5):699–700.

24. Centers for Disease Control and Prevention. Fact sheet: physician prescription of sterile syringes to injection drug users. Atlanta, GA: Academy of Educational Development, 2002. Available at URL: http://www.cdc.gov/idu/facts/physician.htm.

25. Watters JK, Estilo MJ, Clark C, Lorvick JJ. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994;271:115–20.

26. Bluthenthal RN, Kral AH, Erringer EA, Edlin BR. Use of an illegal syringe exchange and injection-related risk behaviors among street-recruited injection drug users in Oakland, California, 1992–1995. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:505–11.

27. Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS 2000;14:605–11.

28. Normand J, Vlahov D, Moses LE, eds. Preventing HIV transmission: the role of sterile needles and bleach. Washington, DC: National Academy Press, 1995.

29. National Institutes of Health. Interventions to prevent HIV risk behaviors. NIH Consensus Statement 11–13 February 1997;15(2):1–41. Available at URL: http://odp.od.nih.gov/consensus/cons/104/104_intro.htm

30. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001;91:42–6.

31. Centers for Disease Control and Prevention. Fact sheet: physician prescription of sterile syringes to injection drug users. Atlanta, GA: Academy of Educational Development, 2002. Available at URL: http://www.cdc.gov/idu/facts/aed_idu_dis.htm.

32. Broers B, Morabia A, Hirschel B. A cohort study of drug users’ compliance with zidovudine treatment. Arch Intern Med 1994;154:1121–7.

33. Salomon N, Perlman DC, Rubenstein A, Mandelman D, McKinley FW, Yancovitz SR. Implementation of universal directly observed therapy at a New York City hospital and evaluation of an out-patient directly observed therapy program. Int J Tuberc Lung Dis 1997;1:397–404.

34. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. AIDS 2000;14:151–5.

35. Harrison K, Vlahov D, Jones K, Charron K, Clements ML. Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:386–90.

36. Gourevitch MN, Wasserman W, Panero MS, Selwyn PA. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. J Addict Dis 1996;15:93–104.

37. Marco A, Cayla JA, Serra M, et al. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Eur Respir J 1998;12:967–71.

38. Smirnoff M, Goldberg R, Indyk L, Adler JJ. Directly observed therapy in an inner city hospital. Int J Tuberc Lung Dis 1998;2:134–9.

39. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001;34:188–93.

40. Sylvestre DL, Aron R, Greene DR, Perkins P. Treating hepatitis C in recovering injection drug users (abstract #2886). Gastroenterology 2001;120:A-568.

41. Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years’ follow-up. Eur Addict Res 2002;8:45–9.

42. Edlin BR. Hepatitis C prevention and treatment for substance users in the United States: acknowledging the elephant in the living room. Int J Drug Policy (in press).
 

 


Main New and Noteworthy                    Conference Index           Home

Injection Drug Use and Hepatitis C
HTML© 2002 Medical Advocates for Social Justice